Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
about
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsEstablishment of a novel cell-based assay for screening small molecule antagonists of human interleukin-6 receptor.Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registrySafety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial.Tocilizumab in the treatment of rheumatoid arthritis and beyond.Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?The role and therapeutic targeting of IL-6 in rheumatoid arthritis.The role of IL-6 in host defence against infections: immunobiology and clinical implications.Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.Tocilizumab: A Review in Rheumatoid Arthritis.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analy
P2860
Q27024465-2F6F49E8-3C1C-4E34-BE55-00FD9BDACD0DQ30962462-0EC5EC7D-66FD-44C9-96A0-41BF6182C065Q33809045-2F0AEED2-87C5-4059-A3F8-D88324467E23Q34451985-DE4052D1-DC77-4D8D-8DC6-F3193BE62891Q34656204-7D0D8210-B553-4EFC-8712-83A092EB5344Q34818996-3F466C79-C50C-4064-87B7-9BBCC66BD25CQ35143956-AD0FA325-6027-42F9-9FB5-48C524DE9392Q35258244-8ED451AC-1A1B-449C-BA31-00DE6CF0A6DCQ35674568-FD0163C2-8607-4881-BAA6-9F2FF3CD435EQ36677277-DAA3FE83-44DB-4404-8B45-C61034219EA7Q37398907-BF0C549F-C669-426D-9270-27D4C9EFCCDBQ37502434-4D447834-6074-48D9-828A-B2E23212D98CQ37682799-6D8B49CC-E8B2-4C1A-9BA7-7C7E7CC32E8AQ37715956-3DE37AAD-5020-4878-B954-B1D28300B14FQ38164315-54D9C25F-580E-480C-8649-8BC4E3BF773AQ38255855-B6A8FC16-0D28-4842-A4D2-01A4E1E6DB5DQ38676903-BE13E208-35F9-4746-9E9B-1A58F4FEB683Q38685086-7556914E-5F53-4795-B761-B495609B5AA5Q38725223-93500085-88FD-4302-B670-044A6358CAB8Q40169531-B967B5C7-0481-4740-A61A-C22A5FEB2728Q40377000-886C8C77-2E1C-4D4F-B74C-31AA17BD85ECQ41187128-ED8B18BE-CA4C-4342-A415-1E35A83920BAQ41693369-FA1E40EE-7531-49FF-9B4C-06480BE0EEE4Q42667803-8646AE34-8C3F-4D56-9516-75619BDD747DQ43280791-970F0B1C-F69F-4FB4-A4A3-9FE041493475Q43444262-742A35AD-649D-440C-95B9-03DCB837E5E7Q47132835-54E3C8CE-7CFA-4A3C-810F-689A3DFDA7E9Q47292924-967A86F6-9B0D-4B0A-ACCE-CBA517AF84C8Q48610087-D41414C7-01A8-411E-ADD5-FD3C118E48C2
P2860
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Tocilizumab in patients with a ...... udy close to clinical practice
@ast
Tocilizumab in patients with a ...... udy close to clinical practice
@en
type
label
Tocilizumab in patients with a ...... udy close to clinical practice
@ast
Tocilizumab in patients with a ...... udy close to clinical practice
@en
prefLabel
Tocilizumab in patients with a ...... udy close to clinical practice
@ast
Tocilizumab in patients with a ...... udy close to clinical practice
@en
P2093
P2860
P1476
Tocilizumab in patients with a ...... udy close to clinical practice
@en
P2093
Andrea Stancati
Andreas Krause
Andrew J K Ostör
Corrado Bernasconi
Jean Sibilia
José Alvaro-Gracia
José Andrés Román Ivorra
Karel Pavelka
Michael T Nurmohamed
Vivian P Bykerk
P2860
P304
P356
10.1136/ANNRHEUMDIS-2011-201087
P407
P577
2012-05-21T00:00:00Z